Omnicell, Inc.

NASDAQ:OMCL

Medical - Healthcare Information Services

Healthcare
$34.66 -1.49%

-$0.58 today

Market cap
$1.59B
Beta
0.96
P/E (TTM)
84.1
EPS (TTM)
$0.45
52W Low $26.85High $55.00

Volume 0.34M

Average 0.57M

OMCL Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Omnicell, Inc.NASDAQ: OMCL

Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026

Other non-cash items declines year over year

Q1 FY2026 other non-cash items of $619K fell 26.8% year over year, ahead of the -56.4% change in trailing-twelve-month other non-cash items. Sequentially, it fell 95.9% from the prior quarter. Over 3 fiscal years it compounded at -37.8% a year.

Context

  • Other non-cash items amounted to 0.3% of revenue in FY2025, unchanged from a year earlier.
  • Other non-cash items increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -26.8% holds above the trailing-twelve-month pace of -56.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$619K-95.9% QoQ
Last fiscal yearDec 2025
$3.74M+41.5% YoY
LTMMar 2026
$17.46M-56.4% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-26.8%——
1 year+41.5%——
3-year CAGR-37.8%——
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
3.74M USD
Year-over-year change
+41.5%
4-year CAGR
-36.1%

Other Non-Cash Items vs competitors

How OMCL compares with its peers on the latest reported figures

  • OMCL's LTM Mar 2026 other non-cash items of $17.46M is the 6th largest of the 11 companies compared; the peer median is $8.71M.
  • Its year-over-year change of -56.4% is the 7th highest of 11, against a peer median of -16.2%.
  • Other non-cash items amounts to 1.4% of revenue for OMCL, versus a peer median of 1.2%.
OMCL Competitors Peer median
Other Non-Cash Items for OMCL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SDGRSchrödinger, Inc.LTM Sep 2026$184.73M -1171.1%—68.6%
GDRXGoodRx Holdings, Inc.LTM Mar 2026$54.97M +315.3%-22.7%7.0%
OMDAOmada HealthLTM Mar 2026$30.95M +401.5%+73.3%10.9%
TDOCTeladoc Health, Inc.LTM Mar 2026$28.06M -96.7%-81.0%1.1%
PGNYProgyny, Inc.LTM Jun 2026$26.73M +10.1%+13.5%2.0%
OMCLOmnicell, Inc.LTM Mar 2026$17.46M -56.4%-37.8%1.4%
ASTHAstrana Health, Inc.LTM Mar 2026$10.02M +128.1%-10.6%0.3%
TXG10x Genomics, Inc.LTM Jun 2026$7.4M +3875.0%-4.2%1.2%
PHRPhreesia, Inc.LTM Apr 2026$1.37M -42.5%-2.6%0.3%
UFPTUFP Technologies, Inc.LTM Jun 2026$61K -106.1%—0.0%
SSIISS Innovations International, Inc.LTM Mar 2026$7.95K -99.7%+34.0%0.0%
Peer median (excluding OMCL) $8.71M-16.2%-3.4%1.2%

Competitors are the stored peer set for OMCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income77.85M5.65M(20.37M)12.53M2.05M
Depreciation & Amortization84.93M99.17M95.56M89.76M86.63M
Deferred Income Tax(3.27M)(37.32M)(11.05M)(14.86M)(1.29M)
Stock-Based Compensation53.16M68.25M55.3M39.32M44.5M
Change in Working Capital(3.34M)(73.47M)43.67M58.33M(8.33M)
Accounts Receivables(40.97M)(60.36M)38.74M(5M)41.42M
Inventory(25.7M)(30.12M)38.02M5.39M(11.23M)
Accounts Payables29.08M(7.75M)(17.53M)7.21M(9.28M)
Other Working Capital34.24M24.76M(15.56M)50.73M(29.25M)
Other Non-Cash Items22.48M15.5M17.98M2.64M3.74M
Operating Cash Flow231.81M77.78M181.09M187.72M127.3M
Capital Expenditures(28.97M)(60.74M)(41.47M)(36.46M)(40.42M)
Acquisitions (Net)(354.16M)2.07M000
Purchases of Investments00000
Sales of Investments0(15.35M)0(10.4M)(10.17M)
Other Investing Activities(29.37M)15.35M0(5.93M)(9.78M)
Investing Cash Flow(412.5M)(58.67M)(55.02M)(52.79M)(60.36M)
Debt Repayment00(2.97M)(225.46M)(175M)
Common Stock Issued040.18M23.22M38.58M16.87M
Common Stock Repurchased(16.29M)(52.21M)00(77.6M)
Dividends Paid00000
Other Financing Activities63.65M(8.93M)3.17M(48.7M)17.42M
Financing Cash Flow47.36M(20.95M)23.42M(235.58M)(218.32M)
Effect of Forex Changes(974K)(944K)(1.35M)(1.72M)3.8M
Net Change in Cash(134.3M)(2.79M)148.14M(102.37M)(147.58M)
Free Cash Flow202.84M17.04M139.62M151.26M86.89M

Omnicell, Inc.

NASDAQ:OMCL

Intrinsic Alpha fair value

Locked

Current Price

$34.66

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.